RIGL
Rigel Pharmaceuticals Inc
48.10$
-1.4%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -14.5% | -40.7% | +52.4% | +16.8% | +6.1% | -25.2% | +51.6% | -19.8% | -12.7% | +39.9% | +213.2% | |
| – | -14.3% | -40.9% | +54.1% | +16.7% | -13.1% | -25.2% | +73.6% | -25.0% | -14.4% | +36.1% | +77.8% | |
| – | +185.8% | -59.4% | +117.2% | +99.3% | -70.5% | +34.9% | -37.8% | +29.5% | +34.0% | +73.1% | -28.5% | |
| – | -11.8% | -40.8% | +54.8% | +11.0% | -23.7% | -41.5% | +118.0% | -53.4% | -2.2% | +35.8% | +100.4% | |
| – | -96.5% | – | – | – | +148.0% | +58.0% | -3.1% | +160.6% | -24.2% | +36.2% | +24.4% | |
| – | – | – | – | – | +51.5% | +21.0% | +303.9% | +37.8% | -39.4% | +8.7% | +91.7% | |
| – | -35.7% | -28.3% | -24.3% | +58.5% | +55.7% | +23.9% | +344.2% | -92.8% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | -7.2% | +95.3% | -8.7% | |
| – | +55.9% | -42.8% | -20.1% | +58.3% | +220.7% | -18.6% | +79.4% | +8.0% | -1.4% | +10.2% | -24.0% | |
| – | +141.0% | -33.2% | -18.8% | +51.2% | +109.9% | -29.8% | +55.6% | +2.6% | -18.3% | +18.8% | +56.8% | |
| – | +7.2% | +7.2% | -91.2% | – | – | +18.6% | +14.7% | -88.5% | +599.1% | -4.6% | +302.6% | |
| – | +71.3% | +101.3% | -52.6% | +142.5% | -35.0% | -10.7% | +2.4% | +493.1% | -68.3% | -53.2% | +115.4% | |
| – | – | – | – | – | – | +102.0% | +0.5% | +98.1% | +32.8% | +0.1% | -57.1% | |
| – | -28.7% | -39.8% | +82.9% | +9.2% | -51.0% | -36.8% | -10.7% | -144.8% | – | – | +11,806.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.9% | +6.7% | +33.8% | +27.1% | +4.3% | +0.8% | +1.0% | +1.1% | +0.9% | +1.6% | +6.5% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.